GH Dec 2025 20.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:57PM EDT. Market open.
Loading interactive chart…
- Zacks
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
- Simply Wall St.
Even after rising 7.4% this past week, Guardant Health (NASDAQ:GH) shareholders are still down 74% over the past three years
It is doubtless a positive to see that the Guardant Health, Inc. ( NASDAQ:GH ) share price has gained some 58% in the...
- Business Wire
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
PALO ALTO, Calif., June 04, 2024--Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498. These genes, or cancer biomarkers, enable oncologists to identify the targeted therapies or treatment strategies that are most effective for patients with advanced cancer. In addition to the panel expansion, Guardant has improved the
© 2024 Yahoo. All rights reserved.